华熙生物（688363）：坚定变革与战略性投入，25年预计触底反弹

Investment Rating - The report maintains an "Outperform" rating for the company [2][7]. Core Insights - The company is undergoing strategic transformations and significant investments, with expectations of a rebound in 2025 after a challenging period [1][7]. - The 2024 revenue is projected at 5.371 billion yuan, a decline of 11.6% year-on-year, while the net profit attributable to shareholders is expected to be 174 million yuan, down 70.6% year-on-year [6][12]. - The company is focusing on management reforms and forward-looking investments to lay a foundation for future growth, including supply chain improvements and R&D in emerging fields [7][8]. Financial Data Summary - Total revenue for 2023 is 6.076 billion yuan, with a projected increase to 5.680 billion yuan in 2025, reflecting a growth rate of 5.7% [6][14]. - The gross profit margin for 2024 is expected to be 74.1%, an increase of 0.75 percentage points year-on-year, while the net profit margin is projected at 3.1%, a decrease of 6.5 percentage points year-on-year [7][8]. - The company anticipates net profits of 451 million yuan in 2025, with corresponding price-to-earnings ratios of 52, 45, and 39 for the years 2025, 2026, and 2027 respectively [7][14].